Tenet Healthcare: Of This Current Report On Form 8k And The Press Releases Attached Hereto As Exhibit 99.1 And Exhibit 99.2 Are Furnished And Shall Not Be Deemed “filed” For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended (the “exchange Act”), Or Otherwise Subject To The Liabilities Under That Section And Shall Not Be Deemed To Be Incorporated By Reference Into Any Filing Of The Registrant Under The Securities Act Of 1933, As Amended, Or The Exchange Act, Unless Specifically Identified Therein As Being Incorporated By Reference, Other Events, Financial Statements And Exhibits

Item 7.01 of this Current Report on Form 8-K and the press releases attached hereto as Exhibit 99.1 and Exhibit 99.2 are furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Exchange Act, unless specifically identified therein as being incorporated by reference.Item 7.01.Regulation FD Disclosure.On November 3, 2025, Tenet Healthcare Corporation (the “Company”) issued a press release announcing the commencement of private placement offerings of $1.5 billion in aggregate principal amount of its senior secured first lien notes due 2032 and $0.50 billion in aggregate principal amount of its senior notes due 2033.A copy of the press release is furnished as Exhibit 99.1 attached hereto and is incorporated herein by reference.Additionally, on November 3, 2025, the Company issued a press release announcing pricing of $1.5 billion in aggregate principal amount of its 5.500% senior secured first lien notes due 2032 (the “first lien notes”) and the upsizing and pricing of $0.75 billion in aggregate principal amount of its 6.000% senior notes due 2033 (the “senior notes” and together with the first lien notes, the “notes”).The closings of the sales of the notes are expected to occur on November 18, 2025, and are subject to customary closing conditions.A copy of the press release is furnished as Exhibit 99.2 attached hereto and is incorporated herein by reference.The first lien notes will be guaranteed by certain of the Company’s subsidiaries and secured on a first lien priority basis by a pledge of the capital stock and other ownership interests of certain of the Company’s subsidiaries.The first lien notes will be effectively senior to the Company’s existing and future indebtedness secured on a more junior basis, as well as unsecured indebtedness and other liabilities, to the extent of the value of the collateral securing such borrowings. The senior notes will be the Company’s unsecured obligations and will rank equally in right of payment with its existing and future senior unsecured obligations, will rank senior in right of payment to all of the Company’s existing and future unsecured subordinated obligations, will be effectively subordinated to all of the Company’s existing and future senior secured obligations, including the first lien notes, to the extent of the value of the collateral securing the Company’s senior secured obligations and will be structurally subordinated to all obligations and liabilities of the Company’s subsidiaries to the extent of the value of the assets of such subsidiaries.The Company intends to use the net proceeds from the sale of the notes, after payment of fees and expenses, to finance, together with cash on hand, the redemption of all $1.5 billion outstanding of its 6.250% senior secured second lien notes due February 2027 (the “2027 Notes”) and the partial redemption of $0.75 billion outstanding of its 6.125% senior notes due October 2028 (the “2028 Notes”).Item 8.01.Other Events.On November 3, 2025, the Company issued a notice of conditional full redemption to the holders of its 2027 Notes and a notice of conditional partial redemption to the holders of its 2028 Notes. The 2027 Notes will be redeemed on November 19, 2025, and the 2028 Notes will be partially redeemed on November 19, 2025.Item 9.01.Financial Statements and Exhibits.(d) ExhibitsExhibit No.Description99.1Press Release issued by the Company on November 3, 2025, announcing the commencement of the offering of the notes.99.2Press Release issued by the Company on November 3, 2025, announcing the pricing of the notes.104Cover Page Interactive Data File (embedded within the inline XBRL document)SIGNATUREPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.TENET HEALTHCARE CORPORATIONDate: November 3, 2025By:/s/ THOMAS ARNSTName:Thomas ArnstTitle:Executive Vice President, Chief Administrative Officer, General Counsel and Corporate Secretary

Інші новини компанії